The American Journal of Pathology
Volume 178, Issue 4 , Pages 1478-1488, April 2011

Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer Cells

  • Timo Gaiser

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Jordi Camps

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Sandra Meinhardt

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Danny Wangsa

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Quang Tri Nguyen

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Sudhir Varma

      Affiliations

    • Bioinformatics and Computational Biosciences Branch, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
  • ,
  • Claudia Dittfeld

      Affiliations

    • Tumor Pathophysiology, OncoRay - National Center for Radiation Research in Oncology, Dresden University of Technology, Germany
  • ,
  • Leoni A. Kunz-Schughart

      Affiliations

    • Tumor Pathophysiology, OncoRay - National Center for Radiation Research in Oncology, Dresden University of Technology, Germany
  • ,
  • Ralf Kemmerling

      Affiliations

    • Institute for Pathology, Paracelsus Medical University, Salzburg, Austria
  • ,
  • Maria R. Becker

      Affiliations

    • Dermatology Branch, and the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Kerstin Heselmeyer-Haddad

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Thomas Ried

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationAddress reprint requests to Thomas Ried, M.D., Section of Cancer Genomics, National Institutes of Health, Building 50, Room 1408, 50 South Drive, Bethesda, MD 20892

Accepted 23 December 2010. published online 22 April 2011.

Colorectal carcinomas (CRC) might be organized hierarchically and contain a subpopulation of tumorigenic, putative cancer stem cells that are CD133 positive. We studied the biological and genetic characteristics of such cells in CRC cell lines and primary tumors. Three CRC cell lines were sorted in CD133 positive and negative fractions. The respective genetic aberration profiles were studied using array comparative genomic hybridization (aCGH) and expression profiling. Tumorigenicity for each cellular population was tested by injection into nude mice. Additionally, we compared CD133+ and CD133− cells of 12 primary colorectal tumors using laser capture microdissection and aCGH. Three of five CRC cell lines displayed both CD133+ and CD133− cells, but tumorigenicity of these subfractions did not differ significantly and aCGH revealed essentially identical genomic imbalances. However, 96 genes were differentially expressed between the two populations. Array comparative genomic hybridization analysis after laser capture microdissection of CD133+ and CD133− areas in primary colorectal tumors revealed genetic differences in 7 of 12 cases. The use of cell lines for studying genomic alterations that define cancer stem cell characteristics, therefore, seems questionable. In contrast, CD133+ cells in primary cancer samples showed a unique genomic aberration profile. In conclusion, our data suggest that CD133 positivity defines a genetically distinct cellular compartment in primary CRC, which potentially includes tumor initiating cells.

 

 Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. T.G. is supported by a fellowship within the post doctorate program of the Mildred Scheel Foundation. The work performed by the group of LAKS (Tumor Pathophysiology, OncoRay) was supported by the German Research Foundation (DFG) through a grant (KU 971/7-1). OncoRay is funded by the Bundesministerium fuer Bildung und Forschung in the program “Center for Innovation Competence.”

 Supplemental material for this article can be found http://ajp.amjpathol.org or at doi:10.1016/j.ajpath.2010.12.036.

PII: S0002-9440(11)00026-5

doi:10.1016/j.ajpath.2010.12.036

The American Journal of Pathology
Volume 178, Issue 4 , Pages 1478-1488, April 2011